EFFICACY AND SAFETY OF GOLIMUMAB AS ADD-ON THERAPY TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: RESULTS OF THE GO-MORE STUDY IN ROMANIA
Romanian Journal of Rheumatology · 2015
DOI: 10.37897/rjr.2015.4.4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Romanian Journal of Rheumatology, 2015. Verfasst von Simona Rednic und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
GO-MORE was an open-label, multinational, prospective observational study in patients with active rheumatoid arthritis (RA) in typical clinical practice settings in 40 countries. The trial involved patients with active rheumatoid arthritis despite treatment with disease modifying antirheumatic drugs (DMARDs) and naïve to biological agents. Considering the different countries demographic or disease characteristics, we analysed the efficacy and safety data of the Romanian subpopulation in this paper.
Method
The patients received subcutaneous GOL 50 mg once a month for a period of 6 months. The primary endpoint was the percentage of patients with a good and moderate EULAR DAS28-ESR response after 6 months of treatment.
Results
A total of 51 patients with active RA with an average disease duration of 3.53 years and an average DAS28 of 6.15 at baseline were included. All patients were taking DMARDs (66% patients were taking methotrexate (MTX) and 23.5% leflunomide (LEF) in monotherapy; the others were taking other background therapies or combinations of them). All these 51 patients received GOL 50 mg once a month. After 6 months 78.4% of patients showed a good or moderate EULAR response, most of them (68.6%) after the first administration; 27.5% showed low DAS28-ESR and 7.8% were in remission. GOL was well tolerated and the safety profile was consistent with the findings of previous studies. The number of serious side effects (12%) or which lead to discontinuation of therapy (8%) was generally low.
Conclusions
The addition of subcutaneous GOL 50 mg once a month to different DMARDs in patients with active RA yielded a moderate or good EULAR DAS28-ESR response after 6 month in a proportion of 78.4% of patients in Romania. The response was observed after the first administration of GOL. The safety profile is consistent with other clinical trials with antiTNFi in RA with no new safety signals detected.
Zitieren
APA
Rednic, S., Parvu, M., Codreanu, C., Ancuta, I., Suta, M., Rosu, A., Chireac, R., Petcu, L., & Ionescu, R. (2015). EFFICACY AND SAFETY OF GOLIMUMAB AS ADD-ON THERAPY TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: RESULTS OF THE GO-MORE STUDY IN ROMANIA. Romanian Journal of Rheumatology. https://doi.org/10.37897/rjr.2015.4.4
Vancouver
Rednic S, Parvu M, Codreanu C, Ancuta I, Suta M, Rosu A, et al. EFFICACY AND SAFETY OF GOLIMUMAB AS ADD-ON THERAPY TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: RESULTS OF THE GO-MORE STUDY IN ROMANIA. Romanian Journal of Rheumatology. 2015. doi:10.37897/rjr.2015.4.4
BibTeX
@article{Rednic2015,
author = {Rednic, Simona and Parvu, Magda and Codreanu, Catalin and Ancuta, Ioan and Suta, Maria and Rosu, Anca and Chireac, Rodica and Petcu, Lorena and Ionescu, Ruxandra},
title = {EFFICACY AND SAFETY OF GOLIMUMAB AS ADD-ON THERAPY TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: RESULTS OF THE GO-MORE STUDY IN ROMANIA},
journal = {Romanian Journal of Rheumatology},
year = {2015},
doi = {10.37897/rjr.2015.4.4}
}
EUVIMED